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Abstract  
Nanobiotechnology is a field of biomedical application of nanosize system which is a rapidly developing area within 
nanotechnology among these nonmaterial, gold nanoparticles (AuNPs) which receive a significant attention due to their 
unique physical, chemical and biological properties. AuNPs and bio-conjugated AuNPs have been widely used in cancer 
treatment besides other application on cancer detection and diagnosis. In this study the potential therapeutic effects of 
polyclonal Antimyeloma antibody (AbMM) conjugated to AuNPs in comparison with naked (AbMM) or AuNPs alone in 
modulation of proliferation capacity in vitro and different stages of MM cell cycle have been evaluated besides evaluation of 
their effects on tumor growth delay. Effect of AuNPs , (AbMM) and (Nanogold -Antimyeloma Antibodies conjugate) (gold-
AbMM) on growth of myeloma cells showed decreasing in multiple myeloma SP2OR (MM) viability with increasing dose of 
these treatments compared to that of control also a significant enhancement in the apoptosis after conjugation of Nanogold to 
the Antimyeloma was observed. The induction of apoptosis with gold-AbMM was significantly higher than the MM cells 
exposed to only AbMM or AuNPs. The study concluded that the efficacy of (gold-AbMM) on induced myeloma growth 
inhibition is better than that of individual AuNPs and AbMM. 
 




     Cancer is an abnormal growth of cells caused by multiple 
changes in gene expression leading to deregulated balance of cell 
proliferation and cell death and ultimately evolving into a population 
of cells that can invade tissues and metastasize to distant sites, 
causing significant morbidity (Raymond, 2007). 
     Multiple myeloma is a progressive hematological disease. It is 
a cancer of the plasma cell, an important part of the immune system 
that produces antibodies to help fight infection and disease.  .The 
term MM describes features of this disease it’s found in multiple sites 
in bone Marrow (Myth) with accumulation of tumor (oma) cells. 
Under normal Condition plasma cells constitute about 1% of the cells 
in bone Marrow while in MM then cells is overproduced and may 
comprise of 10%. To 80% of Cells in bone marrow clinically. It is 
characterized by high level of parameters in blood and /or urine lytic 
bone lessons, anemia renal dysfunction (Mukherjee and 
Bhattacharya, 2008) elevated level of Many cytokines include 
(VEGF). Current treatments include Combination of chemotherapy 
and Stem cell transplantation treatment of chemotherapy includes 
using alkaylating agents and Thalidomide. However none of these 
therapeutic Modules is curative and in most patients the disease will 
need further therapy. 
     Due to the highly heterogeneous nature of the disease, the 
main challenge to cancer therapists today is to deliver drugs that can 
be specifically targeted to the different ‘‘hallmarks’’ of cancer growth.  
     Attempts to treat cancer with polyclonal antibodies, in the form 
of anti-tumor sera, date back to the 1880s (Currie et al., 1972). 
Treatment of mice with allogeneic anti-tumor serum was shown to 
prevent development of a transplantable tumor. Furthermore, 
occasional successful treatment of human malignancies, such as 
melanoma and renal cell carcinoma, with anti-tumor sera derived 
from experimental animals or from humans, has been reported. 
Finally, intravenous administration of human IgG, pooled from 
normal donors, was shown to inhibit growth and limit the spread of 
tumor cells (Jonsson et al., 2000). 
     Colloid gold nanoparticles are currently being developed as a 
possible drug delivery technology to fight cancerous solid tumors. 
The gold nanoparticles could be safely administrated and used to 
enhance the tumor dose during radiation therapy. Also, the use of 
gold nanoparticles seems more promising than earlier methods 
because of the high atomic number of gold and because 
nanoparticles can more easily penetrate the tumor vasculature. 
(Azzam and Morsy, 2008).    
     Biocompatible gold nanoparticles labeled with specific 
targeting molecules (antibodies-proteins) are playing incredible role 
in cancer treatment and diagnosis (Salata, 2004). In this paper we 
investigate the potential therapeutic effects of polyclonal 
Antimyeloma antibody (AbMM) conjugated to AuNPs in comparison 
with naked (AbMM) or AuNPs alone in modulation of proliferation 
capacity in vitro and different stages of MM cell cycle beside 
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evaluation their effects on tumor growth delay in vivo.  
 
MATERIALS AND METHODS 
 
1. Preparation of Colloidal Nanogold (Gold Nanoparticles (AuNPs) of 
20 nm Diameter):This type of AuNPs was prepared according to 
(Azzam et al., 2009). 
2. Production of Antimyeloma Antibodies: Production of Antimyeloma 
Antibodies was carried out by using seven healthy female mature 
White New-Zealand rabbits, 2-3 Kg. They were immunized with 
myeloma cells SP2OR to raise Antimyeloma antibodies according 
to (Hoppe et al., 1971).   
3. Preparation of Nanogold-Antimyeloma Antibodies conjugate: 
Nanogold - Antimyeloma Antibodies conjugate prepared according 





     The antitumor activity for the compounds under investigation 
was carried out on myeloma cell line SP2OR compared to control. 
The method used is the trypan blue exclusion test of Mclimans et al. 
(1957).  As following:  Myeloma cells were cultured in the culture 
medium. a three 24 well plates was prepared as follows 1 ml of 
myeloma cells was added into the first row of the plate and mixed 
well the contents of the wells then serial dilution was performed 
between wells of the first row and the wells of other rows after that 
1ml of media was added into all wells of the plate and the plate 
mixed well. 
     The colloid Nanogold, Antimyeloma antibodies and their 
conjugate serum were diluted in culture media to prepare following 
doses (5, 10, 15, 20 and 25mg/ml) and (5, 10, 15, 20 and 25µg/ml) 
for colloidal gold nanoparticles, (Au-AbMM) and AbMM respectively 
each dose added to each plate and incubated at 37ºc for 24 hours 
and the total count and viability were calculated according to 
(Mclimans et al., 1957). The effective dose then added to another 
new plate and incubated at 37ºc for 6 days and the total count and 




First: Induction of tumor in mice (ascites)    
 
     A line of myeloma cell (SP2OR) was used in the induction 
of ascites described by (Harlow and David, 1988). Treatment 
was started study after development of measurable tumor.   
 
Second: Effect of treatment on tumor bearing mice:  
 
     This experiment was carried out using 5 groups of mice each 
comprise six   mice. The first group was the  positive control 
group, second control (without any treatment), the mice of the third 
group were injected  i.p with 2.5 mg/kg.b.wt/day of ( colloidal 
solution of gold nanoparticles in size around 20 nm ) 
(BarathManiKanth et al., 2010) and the mice of the fourth group were 
injected  i.p with 2.5 µg/kg.b.wt/day of  (serum containing 
Antimyeloma antibodies)  and the mice of the fourth group were 
injected  i.p with 2.5 mg/kg.b.wt/day of (Nanogold - Antimyeloma 
Antibodies conjugate)  kept in cages for recommended times (1, 2, 
3, 4, 5 and 6 day). Ascites fluid was withdrawn under aseptic 
conditions (ultraviolet laminar flow system) from the peritoneal cavity 
of ascites bearing mice at the last day and then undergoes cell cycle 
analysis and apoptosis detection. 
 
RESULTS 




Fig 1. Gold nanoparticles (AuNPs) deposited onto a copper grid for TEM imaging. 










Fig 2. Gold nanoparticles conjugate AbMM deposited onto a copper grid for TEM imaging. 
From a statistical analysis counting 178 AuNPs a mean particle size of 32±3 nm was determined. 
 
Effect of colloid nanogold on growth of myeloma cells 
 




It was observed that total count per ml and viability% decreased with increasing dose of Nanogold colloid compared to that of control. It was 
observed that at 25 mg/ml the total count per ml reached 5 and viability% became 20% after 24 hours.  
 
Effect of Antimyeloma antibodies on growth of myeloma cells. 
 




It was observed that total count per ml and viability% decreased with increasing dose of Antimyeloma antibodies serum compared to that of 
control. It was observed that at 25 mg/ml the total count per ml reached 5and viability% became 30% after 24 hours.  
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Effect of variable doses of (gold-AbMM) on growth of myeloma cells. 
 
Table 3. Effect of variable doses of (gold-AbMM)) on growth of myeloma cell line SP2OR compared to control after 24 hours. 
 
 
     It was observed that total count per ml and viability% decreased with increasing dose of (gold-AbMM) compared to that of control. It was 
observed that at 25µg/ml the total count per ml reached 3 and viability% reached Zero after 24 hours. 
 




Fig 3. Flow cytometer analysis of cell cycle profile of myeloma cell line (SP2OR) without treatment. 
 
M1=apoptosis, M2=G0/G1 phase [G0 (quiescence state), G1 (GAP1 phase)], M3= S phase [Synthetic phase], M4=G2/M phase [G2 (GAP1 phase), M (Mitosis)], It observed that the 
number of cells in M1 (apoptosis) was 0.03%, M2 (G0/G1 phase) =85.72%, M3 (S phase) =11.11%, M4 (G2/M phase) =13.14% 
 
     It observed that nanogold has remarkable effect on myeloma growth compared to the Antimyeloma Abs and nanogold has more effect 




Fig 4. Flow cytometer analysis of cell cycle profile of myeloma cell- line (SP2OR) after (Nanogold treatment). It observed that the number of cells in M1 (apoptosis) was 
12.77%, M2 (G0/G1 phase) =97.24%, M3 (S phase) =1.49%, M4 (G2/M phase) =1.27%. 
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Table 4. Effective dose of AuNPs, (AbMM) and (gold-AbMM) and their effect on growth myeloma cell line SP2OR compared to control over six days (mean±SD) 
 
Days Parameters measured control 
 
MM cell line treated  
with Nanogold 
(25mg/ml) 
MM cell line 
treated  with 
AbMM (25µg/ml) 
MM cell line treated 
with(gold-AbMM) 
(25mg/ml 
1 Total count 106 ±2.6 52±2.1 57±1.9 40±.98 
Dead count 4±0.9 30±0.7 35±3 29±.65 
Viable count 102±3.1 22±1.3 22±0.43 11±1.1 
Total count per ml×10⁴ 53±4.2 26±0.8 28.5±2.1 20±1.4 
Viability (%) 96±1.7 42.31±2.9 38.60±3.2 27.25±1.6 
2 Total count 127±4.6 34±1.7 42±0.3 21±2.6 
Dead count 91±0.7 21±0.7 25±0.9 18±0.96 
Viable count 118±3.9 13±0.8 17±1.1 5±0.4 
Total count per  ml×10⁴ 58±1.5 17±0.5 21±0.8 10±1.3 
Viability (%) 92±1.3 38.24±1.6 40.48±1.8 23.33±2.1 
3 Total count 128±6.8 10±0.4 27±0.78 11±0.9 
Dead count 16±0.9 8±0.3 20±0.3 9±0.67 
Viable count 112±6.3 2±0.05 7±0.1 2±0.01 
Total count per ml×10⁴ 64±3.9 5±0.1 13±2.4 5.±.43 
Viability (%) 87.5±1.1 20.00±1.1 25.93±3.1 18.18±1 
4 Total count 168±11.8 10±0.9 12±0.98 7±0.21 
Dead count 40±0.6 9±0.9 10±0.9 7±0.21 
Viable count 128±12.8 1 2±0.01 0 
Total count per  ml×10⁴ 84±4.5 2±1.9 6±0.4 3±1.5 
Viability (%) 76±1.8 10±0.9 16±1.8 0 
5 Total count 177±14.5 1±0.5 6±0.8 3±0.1 
Dead count 41±1.4 1±0.5 5±0.1 3±0.1 
Viable count 129±13 0 1±0.05 0 
Total count per ml×10⁴ 88±7.9 1±0.2 3±0.22 1±0.2 
Viability (%) 73±1.8 0 16±0.87 0 
6 Total count 257±7.9 3±0.1 6±0.1 3 ± 0.2 
Dead count 71±3.4 3±0.1 6±0.1 3  ± 0.2 
Viable count 186±8.4 0 0 0 
Total count per  ml×10⁴ 128±3.8 1 ± 0.08 3±0.05 1±0.3 





Fig 5. Flowcytometer analysis of cell cycle profile of myeloma cell line (SP2OR) after (Antimyeloma antibodies serum) treatment. It observed that the number of cells in 
M1 (apoptosis) was 11.2%, M2 (G0/G1 phase) =92.55%, M3 (S phase) =4.3%, M4 (G2/M phase) =2.7%. 
 





Fig 6. Flow cytometer analysis of cell cycle profile of myeloma cell line (SP2OR) after (Conjugated nanogold - Ab treatment).It observed that the number of cells in M1 




     Synthesis of gold nanoparticles and their conjugate was 
occurred according to standard wet chemical methods as mention 
before and characterization occurred by TEM measurements. The 
TEM micrographs showed spherical gold nanoparticles of 
approximately 26±7 nm and spherical gold nanoparticles conjugated 
AbMM of approximately 32±3 nm size (figures 1, 2). 
1. Effect of antimyeloma antibodies on the growth of myeloma  
 
     The results obtained indicated that T.C/ml and viability (%) 
decreased by increasing treatment concentration compared to that of 
control group and this illustrated that Antimyeloma polyclonal 
antibodies induced myeloma growth inhibition through its cytotoxicity 
to cells via two immune mechanisms include antibody-dependent 
cellular cytotoxicity and complement-dependent cytotoxicity (Ben-
Kasusa et al., 2007). 
 
2. Effect of colloid nanogold on the growth of myeloma  
 
     The results obtained indicated that T.C/ml and viability (%) 
decreased by increasing treatment concentration compared to that of 
control group and this illustrated that Colloidal gold nanoparticles 
induced myeloma growth inhibition through its cytotoxicity to cells via 
inhibit the function of heparin binding growth factors such as 
VEGF165, BFGF and posses anti-angiogenic properties 
(Bhattacharya et al ., 2007).   
 
3. Effect of nanogold-antimyeloma antibodies conjugate) on 
the growth of myeloma  
 
     The results obtained indicated that T.C/ml and viability (%) 
decreased by increasing treatment concentration compared to that of 
control group and this illustrated that (Nanogold - Antimyeloma 
Antibodies conjugate) induced myeloma growth inhibition through its 
cytotoxicity to cells via double efficiently work of colloid Nanogold 
and anti-MM Abs. (Bhattacharya et al., 2004).   
 
4. Influence of effective dose of colloid nanogold, antimyeloma 
antibody and their conjugate on growth myeloma cell line 
SP2OR compared to control over six days. 
 
     The results obtained indicated that Nanogold has remarkable 
effect on myeloma growth compared to the Antimyeloma Abs and 
Nanogold has more effect after conjugation with Antimyeloma Abs 
on the growth and viability of myeloma cells. The recorded data are 
in keeping with (Mukherjee et al., 2007). 
 
5. Cell cycle analysis: 
 
     In this study, a cell cycle analysis was performed for MM cells 
separated from ascites collected  from treated and untreated mice 
the results indicated that AuNPs delayed the cell cycle progression 
as induced cell cycle arrest in G2/M phase and S phase , the 
recorded study proved that Nanogold remarkably induces apoptosis 
compared with AbMM treatment .The remarkable effect of  
Nanogold on MM cell cycle proliferation  is due to 
anti_angioneogenic  properties of Nanogold moreover multiple 
myeloma secrets Number of growth Factor like VEGF,bfGF which 
Nanogold can inhibit leading to the inhibition of  cell proliferation . 
Gold-treated multiple myeloma cells show cell-cycle arrest in the G1-
phase (the phase when chromosomes prepare for replication) by up-
regulation of cell-cycle cyclin-dependent Kinase inhibitor proteins 
p21 and p27 and this lead to induction of apoptosis.  
     The recorded study observed a significant enhancement in 
the apoptosis after conjugation of Nanogold to the Antimyeloma. The 
induction of apoptosis with gold-AbMM was significantly higher than 
the MM cells exposed to only AbMM or GNP and this due to 
significant down regulation of anti-apoptotic proteins and exhibited 
PARP cleavage showed by the gold-AbMM treated cells (Mukherjee 
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